% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • guru1d guru1d Aug 24, 2006 6:49 AM Flag

    EPCT undervaluation

    Instead of several other biotech companies, which
    have 1-2 products in early development stage, Epicept has several late stage development products:
    eg Ceplene, Lidopain NP1, LidoPAIN SP

    Unfortunately Epicepts poor internet presence makes it nearly impossible for the public to realize the potential.

    After EpiCept Completes Patient Enrollment in European Phase III Clinical Trial for LidoPain SP,
    it is to expect with the publication of good results next, because similar
    trials were already successfully finished in the past(US) and eg already licensed to Adolor.

    Also, if you take the time, to hear the latest presentations and watch the online powerpoint presentations, you may reckon that several
    good news come up next.

    This includes LidoPain SP trial results, Ceplene filing and so on...

    As said, compared to other companies
    which has nothing but promises for
    some highly risk products, that
    may be on market in some years, Epicept
    has already several late stage products
    with high market potential and low development risks. So in my opinion, Epicept is totally
    undervaluated and so my recommendation is
    strong buy and hold.

0.21-0.02(-6.67%)4:00 PMEDT